Hedge Fund Database
The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
As of Oct 21, 2026
Arquitos Capital returned -51.9% net of fees in the third quarter of 2026, bringing its year-to-date net performance to -26.5%, compared to the Russell 2000 benchmark return of 13.9% year-to-date. The substantial quarterly drawdown was primarily driven by adverse litigation developments regarding the fund's core holding, where an unfavorable district court patent ruling temporarily impaired the market valuation of its call option contracts. Despite the steep decline, the fund did not liquidate its January 2028 call options and retained exposure throughout the volatility. The investment narrative is entirely anchored in pharmaceutical regulatory and patent litigation resolution. Rather than relying on broad macroeconomic factors such as interest rate shifts or monetary policy regimes, portfolio outcomes are dictated by legal settlements, intellectual property disputes, and commercialization rights in the pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) markets. Portfolio activity and capital allocation are centered on Liquidia Corporation. Following the quarter-end district court decision, Liquidia announced a comprehensive settlement with United Therapeutics resolving all six outstanding legal disputes. The fund manager views the post-settlement risk/reward balance as exceptionally compelling at prevailing market prices and is launching a dedicated special purpose vehicle (SPV) to aggressively expand exposure to the equity opportunity alongside existing fund holdings.
Capitalize on severe market mispricings in high-upside specialty pharmaceutical companies where major litigation overhangs and temporary regulatory disputes obscure durable underlying commercial cash flows.
Liquidia possesses a clear pathway to a $100+ stock price over the next 12 to 18 months driven by Yutrepia in PAH, future pipeline progress in L606, and potential corporate buyout interest.
High Conviction Bullish
Market Conviction
Growth Outlook
Risk Appetite
Capital Deployment
Forward Guidance
Language Signal
Perceived Risk
Opportunity Density
Time Horizon
Top Conviction Themes
Every insight in this database connects to the original source. Read the actual thesis, see the actual concerns, and make your own call.
Buyside Digest has no business relationship, partnership, agency, sponsorship, endorsement, or affiliation with Arquitos Capital Management or any other manager whose content appears on the Service, except where expressly stated. We do not receive Manager Content directly from managers in most cases; content is collected from publicly available sources. Managers have not necessarily reviewed, approved, authorized, or endorsed our display of their content, our editorial commentary, our metadata extraction, or our classifications. Use of a manager’s name is for accurate attribution and identification purposes only, under principles of nominative fair use.
Buyside Digest does not independently verify the regulatory status, registrations, licensing, qualifications, credentials, or professional standing of managers whose content appears on the Service. We do not represent that managers are properly registered with applicable regulatory bodies, that their content complies with applicable securities laws, or that their performance representations are accurate. Inclusion of a manager in our database is based on the publicly available nature of their content, not on our verification of their regulatory status or content compliance. Users are responsible for conducting their own due diligence on any manager.
Performance data, returns, assets under management (“AUM”), and similar figures displayed on this page are sourced from publicly available manager communications (including investor letters), public filings, or other third-party sources. Buyside Digest does not independently verify performance figures, calculate returns, or audit manager-reported data. Such figures: May be selectively reported by the manager; May use non-standard calculation methodologies; May not reflect fees, expenses, taxes, or other costs; May be inconsistent across reporting periods; May be outdated. Past performance is not indicative of future results. Performance figures should not be relied upon for investment decisions without independent verification. Users should request audited performance data directly from the manager and conduct their own due diligence.